HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors presents unresolved therapeutic problems for HER2-positive gastric cancer. The present study describes investigations with AUY922, a heat shock protein 90 (HSP90) inhibitor, in primary lapatinib-resistant (ESO26 and OE33) and lapatinib-sensitive gastric cancer cells (OE19, N87, and SNU-216) harboring HER2 amplification/over-expression. In order to investigate whether AUY922 could overcome intrinsic and acquired resistance to HER2 inhibitors in HER2-positive gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (OE19/LR and N87/LR) by continuous exposure to lapatinib in vitro. We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines. In conclusion, AUY922 showed a synergistic anti-cancer effect with lapatinib and sensitized gastric cancer cells with intrinsic resistance to lapatinib. Dual inhibition of the HSP90 and HER2 signaling pathways could represent a potent therapeutic strategy to treat HER2-positive gastric cancer with intrinsic and acquired resistance to lapatinib.
Abstract
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors presents unresolved therapeutic problems for HER2-positive gastric cancer. The present study describes investigations with AUY922, a heat shock protein 90 (HSP90) inhibitor, in primary lapatinib-resistant (ESO26 and OE33) and lapatinib-sensitive gastric cancer cells (OE19, N87, and SNU-216) harboring HER2 amplification/over-expression. In order to investigate whether AUY922 could overcome intrinsic and acquired resistance to HER2 inhibitors in HER2-positive gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (OE19/LR and N87/LR) by continuous exposure to lapatinib in vitro. We found that activation of HER2 and protein kinase B (AKT) were key factors in inducing intrinsic and acquired lapatinib-resistant gastric cancer cell lines, and that AUY922 effectively suppressed activation of both HER2 and AKT in acquired lapatinib-resistant gastric cancer cell lines. In conclusion, AUY922 showed a synergistic anti-cancer effect with lapatinib and sensitized gastric cancer cells with intrinsic resistance to lapatinib. Dual inhibition of the HSP90 and HER2 signaling pathways could represent a potent therapeutic strategy to treat HER2-positive gastric cancer with intrinsic and acquired resistance to lapatinib.
참고문헌 (34)
- Bray F, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
- Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 358, pp.36~46 (2008)
- Kang YK, "Capecitabine", cisplatin versus 5-fluorouracil, Ann Oncol, pp.2009, 20[DOI]
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Hecht JR, "Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013", LOGiC--A Randomized Phase III Trial, 2016, pp.34, 443~451
- Satoh T, "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study", J Clin Oncol, 32, pp.2039~2049 (2014)
- 박진주, "FOXO1 Suppression Is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells through MET Upregulation", Cancer Research and Treatment, 50(1), pp.239~254 (2018), 대한암학회
- Chen CT, "MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells", Mol Cancer Ther, 11, pp.660~669 (2012)
- Kim HP, "Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer", Oncogene, 33, pp.3334~3341 (2014)
- Liu L, "Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells:activation of AXL", Cancer Res, 69, pp.6871~6878 (2009)
- Trowe T, "EXEL-7647inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation", Clin Cancer Res, 14, pp.2465~2475 (2008)
- Xu X, "HER2Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2(+) Breast Cancer", Clin Cancer Res, 23, pp.5123~5134 (2017)
- D'Amato V, "Mechanisms of lapatinib resistance in HER2-driven breast cancer", Cancer Treat Rev, 2(41), pp.877~883 (2015)
- Hegde PS, "Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles", Mol Cancer Ther, 6, pp.1629~1640 (2007)
- Wainberg ZA, "Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer", Mol Cancer Ther, 12, pp.509~519 (2013)
- Lee KH, "Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins", Cancer Sci, 102, pp.1388~1395 (2011)
- Mayor-Lopez L, "Comparative Study of 17-AAG and NVP-AUY922in Pancreatic and Colorectal Cancer", Transl Oncol, 7, pp.590~604 (2014)
- Garcia-Carbonero R, "Inhibition of HSP90 molecular chaperones: moving into the clinic", Lancet Oncol, 14, pp.e358~e369 (2013)
- Tillotson B, "Hsp90(heat shock protein 90)inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo", J Biol Chem, 285, pp.39835~39843 (2010)
- Jensen MR, "NVP-AUY922 : a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models", Breast Cancer Res, 10, pp.R33~ (2008)
- Gaspar N, "Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma", Mol Cancer Ther, 9, pp.1219~1233 (2010)
- Eccles SA, "NVP-AUY922 : a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis", Cancer Res 68 (2008)
- Piotrowska Z, "Activity of the Hsp90 inhibitor Luminespib Among Non-Small Cell Lung Cancers Harboring EGFR Exon 20 Insertions", Ann Oncol, 29, pp.2092~2097 (2018)
- Seggewiss-Bernhardt R, "Phase 1", 1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma, 2015, pp.121, 2185~2192
- Modi S, "HSP90inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab", Clin Cancer Res, 17, pp.5132~5139 (2011)
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Berezowska S, "Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas", PLoS One, 8, pp.e69098~ (2013)
- Wang J, "High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer", PLoS One, 8, pp.e62876~ (2013)
- Taipale M, "Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition", Cell, 150, pp.987~1001 (2012)
- Raja SM, "A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells", Cancer Biol Ther, 7, pp.1630~1640 (2008)
- Canonici A, "The HSP90inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells", Invest New Drugs, 36, pp.581~589 (2018)
- Felip E, "Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer", J Thorac Oncol, 13, pp.576~584 (2018)
- Kong A, "Phase 1B", 2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen, 2016, pp.7, 37680~37692